MRKR Marker Therapeutics, Inc. Insider Trading

Director Elms buys 11.1K shares of MRKR at $3.20; stock down 43.5% from 52-week high amid -63.3% revenue decline.

Director Steve Elms purchased 11,085 shares at $3.20 on 2024-12-23, increasing his holdings from 314,285 shares to 325,370 shares. The purchase occurred at a price significantly below the 52-week high of $5.96 and modestly below the current price of $3.37, though the stock has declined 43.5% from peak. The company faces material operational headwinds: quarterly revenue stands at $1,926,020.00 with a net loss of $2,308,192.00, and annual revenue has contracted 63.3% year-over-year. Across Elms's cross-ticker track record, his 5 prior open-market sales show a 0.00% well-timed rate and an average 90-day return of +75.0%, indicating his prior exit decisions have not captured downside protection. This open-market purchase adds a data point but must be evaluated against the company's significant operational deterioration and the director's mixed execution history on prior trades.

10% owner New Enterprise Associates 16, L.P. buys 554,250 shares of MRKR at $3.20; +51.7% increase to 1,625,678 shares

New Enterprise Associates 16, L.P., a 10% owner of Marker Therapeutics, increased its stake by 554,250 shares to 1,625,678 shares at $3.20 per share on 2024-12-23, representing a 51.7% increase from its prior 1,071,428 shares. This is a material accumulation at a price that is -42.6% from the 52-week high of $5.96, coinciding with a period of near-term positive momentum (the stock is up 10.3% over the prior 30 days and 28.6% over 90 days). The context reveals a company under financial stress: Marker Therapeutics reported revenue of $1,926,020.00 for the latest quarter with a net loss of $2,308,192.00, annual revenue declining 63.3% year-over-year, and unprofitable full-year results, producing a $30.5M market cap. The material purchase by a major shareholder while the stock recovers from a depressed level warrants investor attention to whether the investor sees value inflection ahead or is simply managing portfolio exposure at a reduced entry point.